Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?
作者信息
Al Hadidi Samer, Yellapragada Sarvari
机构信息
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston.
Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock.
出版信息
JAMA Oncol. 2021 Oct 1;7(10):1449-1450. doi: 10.1001/jamaoncol.2021.2761.
PMID:34383000
Abstract
摘要
相似文献
1
Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?
JAMA Oncol. 2021 Oct 1;7(10):1449-1450. doi: 10.1001/jamaoncol.2021.2761.
2
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Br J Haematol. 2021 Aug;194(4):784-788. doi: 10.1111/bjh.17541. Epub 2021 May 28.
3
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
Blood Cancer J. 2021 Mar 12;11(3):55. doi: 10.1038/s41408-021-00438-y.
4
Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma.
Oncology (Williston Park). 2023 Apr 25;37(4):166-167. doi: 10.46883/2023.25920993.
5
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Ann Hematol. 2021 Dec;100(12):3057-3060. doi: 10.1007/s00277-020-04293-y. Epub 2020 Oct 2.
6
Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma.
Blood Cancer J. 2023 Jan 11;13(1):11. doi: 10.1038/s41408-023-00785-y.
7
[Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):504-507. doi: 10.3760/cma.j.issn.0253-2727.2023.06.012.
8
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4.
9
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica. 2024 Jul 1;109(7):2331-2336. doi: 10.3324/haematol.2023.284635.
10
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
引用本文的文献
1
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
Biomolecules. 2022 Nov 7;12(11):1647. doi: 10.3390/biom12111647.
Zotero 插件